Cognitive Decline Market To Be Driven By Flexible Usage Of IT Programs And Tools At A CAGR Of 5.8%

New York, United States, 2022-May-19 — /EPR Network/ —

AI-backed computer algorithms (more of sophisticated algorithms), better known as chatbots, are capable of conducting meaningful conversations (human-like) through option-based, textual, or voice-based input. The basic advantage of these chatbots would be smooth sailing on the part of patients in spite healthcare personnel being out of reach at times (due to factors like non-operation hours, disaster-induced overloads over the calls, and likewise). This would result in cutting down on long hours of drug approvals through the US FDA. This would be the functioning of cognitive decline market in the next 10 years.

Owing to rising demand for non-invasive brain stimulation, the global cognitive decline market was valued at over US$ 2 Bn in 2020, and is expected to exhibit a CAGR of 5.8 % over the forecast period (2021-2031).

Cognitive decline is a condition in which the brain does not work as well as it should. According to the Centers of Disease Control and Prevention (CDC) report, the prevalence of cognitive decline in the U.S. is 11.1%. This rising prevalence of cognitive decline is one of the major factors driving the growth of the market.

Non-invasive brain stimulation (NIBS) is gaining traction as a clinically effective tool for identifying and treating a wide range of mental illnesses. Widespread use of NIBS will be contingent on its efficacy as demonstrated in sham-controlled multi-center trials, but current indications point to it having a significant impact on the treatment of disorders seen in a variety of specialties, including neurology, psychiatry, pediatrics, physical therapy, and physical medicine and rehabilitation.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32968

Because non-invasive brain stimulation carries minimal risk, it is associated with fewer side effects and consequences. This will be one of the primary driving forces in the market over the projected period of 2022-2032.

Companies are focusing on developing innovative and competitive products to meet unmet market needs. There are multiple licensing and collaboration agreements for the development and commercialization of products in the areas of cognitive decline. New market entrants are working on an effective pricing strategy. Business units are restructuring initiatives to enhance business effectiveness. Diversification of companies’ efforts is also leading to the development of other generic drugs.

Companies are entering into strategic alliances with other pharmaceutical companies and government bodies for faster development of present pipeline drugs.

Company Profiles:

• Johnson & Johnson Services, Inc.
• Novartis AG, Eisai Co., Ltd.
• Dr. Reddy’s Laboratories Ltd
• Macleods Pharmaceuticals Ltd.
• Medtronic, Abbott, Boston Scientific
• Aleva Neurotherapeutics SA
• PINS Medical Pte. Ltd.
• ElectroCore Inc.
• LivaNova PLC
• ReShape Lifesciences
• NERVANA LLC.
• Parasym Health
• EB Neuro S.p.A
• Neuronetics, Inc.
• Nexstim
• Neurosoft
• ReShape Lifesciences
• BRAINBOX LTD
• Magstim Company Ltd.
• BrainsWay
• MAG & More GmbH.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/32968

Key Takeaways from Market Study

• By product type, drug therapy held 53% market value share in 2020.
• By indication, mild cognitive impairment (MCI) held 78% market value share in 2020.
• Hospitals dominated the cognitive decline market with a share of 39.1% in 2020, owing to more effective treatment within these facilities.
• By region, North America dominated the global cognitive decline market with a value share of around 36.8% in 2020.

 “Positive reimbursement paradigm for cognitive decline and innovative products & solutions for treatment will promote market growth,” says an analyst of Persistence Market Research.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/32968

Market Competition

Key players are focusing on forming strategic partnerships through acquisitions and mergers to enhance their presence across the world, resulting in increased customer base.

• In March 2021, Deutsches Zentrum für Neurodegenerative Erkrankungen and Eisai Co., Ltd. entered into a research agreement to create novel treatments for neurodegenerative disorders, including Alzheimer’s disease (AD).
• In August 2019, electroCore, Inc. announced a research collaboration with the Massachusetts General Hospital to explore non-invasive Vagus nerve stimulation in neuroinflammation.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the cognitive decline market in its latest study, presenting historical demand assessment of 2016 – 2020 and projections for 2021 – 2031.

The research study is based on the product type (drug therapy [cholinesterase inhibitors, NMDA receptor antagonists], non-invasive stimulation devices [vagus nerve stimulators, deep brain stimulators, transcranial magnetic stimulators (TMS)]), indication (mild cognitive impairment (MCI) [amnestic MCI, non-amnestic MCI], dementia), and end user (hospitals, neurology clinics/centres, retail pharmacies, home care settings) across seven key regions of the world.

About us: Persistence Market Research

Contact us:

Persistence Market Research          
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com